Fred Hutchinson Cancer Research Center’s latest findings on cell therapies, repairing immune function, and more will be featured at the 62nd American Society of Hematology Annual Meeting & Exposition, to be held virtually Dec. 5 – 8. Dr. Stephanie Lee, ASH president and Fred Hutch physician-scientist will kick off the meeting with a fireside chat with Dr. Anthony Fauci. She…
Read More

Allen Institute Announces 2020 Next Generation Leaders

The Allen Institute today announced six new Next Generation Leaders, members of a unique neuroscience advisory panel made up of early-career researchers. Now in its seventh year, the Next Generation Leaders Council advises neuroscience research efforts at the Allen Institute, namely the Allen Institute for Brain Science and the MindScope Program. Next Generation Leaders are selected each year through a…
Read More
UW Medicine researchers at the Brotman Baty Institute in Seattle have created two cell atlases that track gene expression and chromatin accessibility during the development of human cell types and tissues. One atlas maps gene expression within individual cells across 15 fetal tissues. The second atlas maps the chromatin accessibility of individual genes within the cells. Together, the atlases provide…
Read More
It’s generally thought that the more critical a gene is to cellular function, the more likely it is be an “old” part of DNA and relatively unchanged by evolution. But new work from scientists at Fred Hutchinson Cancer Research Center, published November 10 in the journal eLife, upends that belief by demonstrating that some essential genes are actually “young” and evolving…
Read More
Using a targeting molecule to concentrate toxic chemotherapy in tumors could hold potential as a treatment for an aggressive subtype of advanced prostate cancer, according to work published November 16 in the journal Clinical Cancer Research. Scientists at Fred Hutchinson Cancer Research Center show that some neuroendocrine prostate cancer cells have high levels of a specific protein marker, and that using this…
Read More
Receptor Life Sciences announced today that the Company was granted a Schedule I research license from the United States Drug Enforcement Agency (DEA). The license is a federal requirement for any scientific or medical personnel who intend to study, prescribe, or otherwise work with Schedule I controlled substances. Under the license, Receptor will research the application of its drug delivery…
Read More
Biotech giant Moderna on Monday announced that its COVID-19 vaccine was 94.5% effective in preventing the disease during Phase 3 trials. Moderna CEO Stéphane Bancel called it a “pivotal moment in the development of our COVID-19 vaccine candidate.” “This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including…
Read More
WRF Postdoctoral Fellows are funded for three years at eligible institutions in Washington state to work on ambitious projects addressing major public needs. The 2020 fellows are: Dr. Daniel Birman, University of Washington Department of Biological Structure Dr. Alison Chase, University of Washington Applied Physics Laboratory Dr. Rossana Colon-Thillet, Fred Hutchinson Cancer Research Center Dr. Jason Coult, University of Washington…
Read More
Fred Hutchinson Cancer Research Center is starting volunteer enrollment for a COVID-19 vaccine trial. The phase 3 study will examine whether AstraZeneca’s AZD1222 vaccine can protect against COVID-19 and also prevent infection with SARS-CoV-2, the virus responsible for the COVID-19 disease. The AZD1222 vaccine study will be conducted by the Vaccine Trials Unit (VTU), a program of Fred Hutch. Visits will occur…
Read More
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a collaboration with GlaxoSmithKline plc (GSK) to use its clonoSEQ® Assay to assess minimal residual disease (MRD) in GSK’s portfolio of hematology products. “We are thrilled to collaborate with GSK to implement…
Read More